LigaChem Biosciences Inc. (KOSDAQ:141080)
South Korea flag South Korea · Delayed Price · Currency is KRW
85,200
-2,400 (-2.74%)
Sep 11, 2026, 3:30 PM KST

LigaChem Biosciences Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
98,782141,553125,89834,14633,41232,157
Revenue Growth
-33.38%12.44%268.71%2.20%3.90%-44.07%
Gross Profit
86,551125,996109,94817,79717,84917,698
Operating Income
-205,708-106,486-20,913-80,822-50,375-27,707
Net Income
-178,730-74,2787,800-73,704-45,092-23,391
Earnings Per Share
-4893.50-2042.00224.00-2595.00-1609.47-970.00
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Pharmaceutical Business
16,05420,39220,53821,34220,33119,226
New Drug Research and Development
82,728121,161105,36012,80413,08112,931
Total
98,782141,553125,89834,14633,41232,157

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
383,856474,548493,94799,925169,946180,814
Total Debt
2,5882,749819.8712,64412,24912,269
Net Cash (Debt)
381,269471,798493,12887,281157,697168,545
Net Cash Growth
-31.79%-4.32%464.99%-44.65%-6.44%82.06%
Net Cash Per Share
10438.3812968.5514189.223072.855628.726986.35

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-191,615-124,53378,476-62,236-7,136-42,049
Capital Expenditures
-2,957-3,050-2,628-1,319-4,164-18,309
Free Cash Flow
-194,572-127,58275,849-63,555-11,300-60,358
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
87.62%89.01%87.33%52.12%53.42%55.04%
Operating Margin
-208.25%-75.23%-16.61%-236.70%-150.77%-86.16%
Pretax Margin
-186.86%-66.33%7.25%-221.83%-142.83%-63.82%
Profit Margin
-180.94%-52.47%6.20%-215.85%-134.96%-72.74%
FCF Margin
-196.97%-90.13%60.25%-186.13%-33.82%-187.70%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--509.64---
Forward PE
-129.3452.0644.5044.5044.50
P/FCF Ratio
--52.41---
PS Ratio
31.7844.6731.5853.5232.7142.05